The Parkinson's Progression Markers Initiative (PPMI), funded by the Michael J. Fox Foundation, is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biological sampling and clinical and behavioral assessments to identify biomarkers of Parkinson's disease progression. The mission of PPMI is to identify one or more biomarkers of Parkinson's disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for Parkinson's Disease.
The CTSDMC is the Data Management Core of PPMI as well as the Statistical Core of PPMI, leading the statistical analyses on the PPMI data and samples.
Learn more at ppmi-info.org.